SyntheticMR announced today that their quantitative imaging software solution SyMRI® has received a CE-mark for its product package SyMRI MSK, which can now be marketed and sold in Europe.

The SyMRI MSK product package provides a fast scan that can help improve patient throughput, produce a range of contrast-weight­ed images, as well as quantitative T1, T2, and PD maps for both clinical and research practices for all MSK anatomies and joints - including spine. Quantitative imaging has shown a lot of potential within MSK applications, particularly for improved cartilage assessment.

'Europe is one of our key markets, and we look forward to introducing our MSK applications in this region,' said Ulrik Harrysson, CEO, SyntheticMR. 'Quantitative imaging has a clear role in MSK and spine imaging. We look forward to bringing this technology to new customer groups as well as to current users of our product package SyMRI NEURO, to help support more informed decisions and improved radiology workflows.'

SyMRI uses a unique scanning sequence to measure the ab­solute properties of the anatomy. The product package SyMRI MSK joins SyntheticMR's growing portfolio of quantitative software solutions, which also includes SyMRI NEURO.

This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 19January 2021.

Attachments

  • Original document
  • Permalink

Disclaimer

SyntheticMR AB published this content on 19 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2021 12:39:01 UTC